Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

Abstract Background Diabetes mellitus is an important risk factor for atrial fibrillation (AF) development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the treatment of type 2 diabetes mellitus (T2DM). Their cardioprotective effects have been reported but whether they prevent AF...

Full description

Bibliographic Details
Main Authors: Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li, Tong Liu
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Cardiovascular Diabetology
Subjects:
Atrial fibrillation
Empagliflozin
SGLT-2 inhibitor
Atrial remodeling
Mitochondrial function
Diabetic rats
Online Access:https://doi.org/10.1186/s12933-019-0964-4

Internet

https://doi.org/10.1186/s12933-019-0964-4

Similar Items